Zhao Rui, Zhou Ye, Shen Huifang, Guan Lijun, Wang Yao, Shen Xinting, Wang Fei, Yao Xinmiao
Food Processing Research Institute, Heilongjiang Academy of Agricultural Sciences, Harbin 150086, China.
Heilongjiang Province Key Laboratory of Food Processing, Harbin 150086, China.
Foods. 2025 Apr 24;14(9):1479. doi: 10.3390/foods14091479.
Dipeptidyl peptidase IV (DPP-IV) inhibitory peptides have emerged as promising functional ingredients for managing type 2 diabetes due to their ability to enhance insulin secretion and improve glycemic control. This review provides a concise overview of current strategies for the preparation and encapsulation of DPP-IV inhibitory peptides, with a focus on food industry application, evaluating bioinformatics for substrate selection, and methods like mild enzymatic hydrolysis, cost-effective fermentation, and high-purity chemical synthesis for peptide production. Challenges associated with incorporating these peptides into food products are addressed, including impacts on sensory properties, stability during processing and digestion, and the need for effective delivery systems to enhance bioavailability. Potential solutions to improve peptide stability and targeted release, such as emulsions, liposomes, and nanoparticles, are explored. Future research directions are outlined, emphasizing the necessity for scalable production methods, co-encapsulation strategies, and consumer acceptance studies to facilitate the commercialization of DPP-IV inhibitory peptides as functional food ingredients. By addressing these key areas, this review aims to provide a theoretical foundation and practical guidance for the development of DPP-IV inhibitory peptides, paving the way for their broader application in the prevention and management of type 2 diabetes.
二肽基肽酶IV（DPP-IV）抑制肽因其增强胰岛素分泌和改善血糖控制的能力，已成为治疗2型糖尿病的有前景的功能成分。本文综述了目前制备和封装DPP-IV抑制肽的策略，重点关注食品工业应用，评估用于底物选择的生物信息学，以及用于肽生产的温和酶解、经济高效发酵和高纯度化学合成等方法。文中讨论了将这些肽纳入食品中的相关挑战，包括对感官特性的影响、加工和消化过程中的稳定性，以及对提高生物利用度的有效递送系统的需求。探讨了改善肽稳定性和靶向释放的潜在解决方案，如乳液、脂质体和纳米颗粒。概述了未来的研究方向，强调了可扩展生产方法、共封装策略和消费者接受度研究的必要性，以促进DPP-IV抑制肽作为功能性食品成分的商业化。通过解决这些关键领域，本文旨在为DPP-IV抑制肽的开发提供理论基础和实践指导，为其在2型糖尿病预防和管理中的更广泛应用铺平道路。
